Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks

Page 5 of 5

01. Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)

Price Reaction after the Price Target Cut: -0.4800 (-18.5328%)

On March 19, H.C. Wainwright analyst Ed Arce made revisions to the price target for Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a prominent player in the pharmaceutical industry. Arce reduced the price target from $14.00 to $12.00. Following this announcement, there was a significant market response, with the stock price witnessing a substantial decline of 18.5328% to $2.11 on the closing bell of the same day. The revised target reflects a more conservative valuation, reflecting potential challenges and uncertainties facing the company. Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) position within the pharmaceutical industry, along with its pipeline of innovative drug candidates and strategic initiatives, were key considerations in Arce’s assessment. Despite the downward revision in the price target, Arce remains cautious about the company’s near-term outlook and believes that Acurx Pharmaceuticals may encounter obstacles in achieving its growth objectives. The significant decrease in the stock price following the price target cut indicates a notable market reaction, underscoring investor concerns about Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) future performance and prospects in the competitive pharmaceutical landscape. Overall, while revising the price target downwards, Arce’s decision to maintain coverage on Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) reflects his cautious outlook on the company’s near-term prospects. The substantial market response highlights the significance of price target adjustments in influencing investor sentiment and market dynamics within the pharmaceutical industry.

You can also take a look at 10 Cheap Clean Energy Stocks To Buy According to Wall Street Analysts and 11 Most Undervalued Cybersecurity Stocks To Buy According To Analysts

Page 5 of 5